A review of calcium channel antagonists in the treatment of pediatric hypertension

Pediatric Drugs

Volumn 8, Issue 6, 2006, Pages 357-373

  Sahney, Shobha ^a  

^a LOMA LINDA UNIVERSITY CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENIDIPINE; BENZOTHIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CYCLOSPORIN A; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFONIDIPINE; FELODIPINE; FLUCONAZOLE; ISRADIPINE; ITRACONAZOLE; KETOCONAZOLE; LABETALOL; MANIDIPINE; NICARDIPINE; NIFEDIPINE; NILVADIPINE; NITROPRUSSIDE SODIUM; PLACEBO; TACROLIMUS; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VASODILATOR AGENT; VERAPAMIL;

ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL OXYGEN TENSION; ARTERY DILATATION; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BRADYCARDIA; BRAIN ISCHEMIA; CALCIUM TRANSPORT; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DIZZINESS; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUCHENNE MUSCULAR DYSTROPHY; EDEMA; ESSENTIAL HYPERTENSION; FATIGUE; FETUS DISTRESS; FLUSHING; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GRAPE JUICE; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; INTOXICATION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; LEG CRAMP; LEG EDEMA; META ANALYSIS; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROTOXICITY; OXYGEN SATURATION; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; PR INTERVAL PROLONGATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RENAL PROTECTION; RENOVASCULAR HYPERTENSION; REVIEW; SEIZURE; SENSORY SYSTEM; SIDE EFFECT; SINUS BRADYCARDIA; SUPRAVENTRICULAR TACHYCARDIA; SUSTAINED RELEASE PREPARATION; SYSTEMATIC REVIEW; TACHYCARDIA; THORAX PAIN; THROMBOPHLEBITIS; UNSPECIFIED SIDE EFFECT;

AMIODARONE; CALCIUM CHANNEL BLOCKERS; CHILD; FELODIPINE; HUMANS; HYPERTENSION; ISRADIPINE; NICARDIPINE; NIFEDIPINE; VERAPAMIL;

EID: 33845504299     PISSN: 11745878     EISSN: 11745878     Source Type: Journal    
DOI: 10.2165/00148581-200608060-00004     Document Type: Review

References (116)

1. National High Blood Pressure Education Program Working Group report on hypertension control in children and adolescents. Update on the 1987 task force report on high blood pressure in children and adolescents. Pediatrics 1996; 98: 649-58
2. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2413-46
3. Zimmer SH, Levy PS, Kass EH. Familial aggregation of blood pressure in childhood. N Engl J Med 1971; 284: 401-4
4. Shear CL, Burke GL, Freedman DS, et al. Value of childhood blood pressure measurements and family history in predicting future blood pressure status: results of 8 years of follow up in Bogalusa Heart Study. Pediatrics 1986; 77: 862-9
5. Jung FF, Inglefinger JR. Hypertension in childhood and adolescence. Pediatr Rev 1993; 14: 169-79
6. American Academy of Pediatrics. Recommendations for preventive pediatric health care (RE 9535). Pediatrics 1995; 96: 1-6
7. National Heart, Lung, and Blood Institute. Report of the Second Task Force on blood pressure control in children. Pediatrics 1987; 79: 1-25
8. National Heart, Lung, and Blood Institute. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents [online]. Available from URL: http:\www.nhlbi.nih.gov/health/prof/ heart/hbp/hbp_ped.htm [Accessed 2006 Jun 28]
9. Lieberman E. Hypertension in childhood and adolescence. In: Kaplan NM, editor. Clinical hypertension. Baltimore (MD): Williams and Wilkins, 1998: 407-20
10. Sinaiko AR. Treatment of hypertension in children. Pediatr Nephrol 1994; 8: 603-9
11. Rocchini AP, Key J, Bondie D, et al. The effect of weight loss on the sensitivity of blood pressure in obese adolescents. N Engl J Med 1989; 321: 580-5
12. Falkner B, Sadowski RH. Hypertension in children and adolescents. Am J Hypertens 1995; 6: 106S-10S
13. Rocchini AP, Katch V, Anderson J, et al. Blood pressure in obese adolescents: effect of weight loss. Pediatrics 1988; 82: 16-23
14. Flynn JT. Pediatric use of antihypertensive medications. Curr Ther Res 2001; 62: 314-28
15. Bauer JH, Reams P, editors. Brenner and Rector's. 6th ed. Angiotensin-converting enzyme inhibitors. Philadelphia (PA): W.B. Saunders, 2000: 2270
16. Gavras I. Bradykinin mediated effects of ACE inhibitors. Kidney Int 1992; 42: 1020-9
17. Kostis JB. Angiotensin-converting enzyme inhibitors. Am J Hypertens 1989; 2: 57-64
18. Williams GH. Converting enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988; 319: 1517-25
19. Heeg JE, de Jong PE, van der Hem GK, et al. Reduction of proteinuria by angiotensin converting enzyme inhibition. Kidney Int 1987; 32: 78-83
20. De Zeeuw D, Heeg JE, Stelwagen T, et al. Mechanism of antiproteinuric effect of angiotensin-converting enzyme inhibition. Contrib Nephrol 1990; 83: 160-5
21. Giatras I, Lau J, Levey A. Effect of angiotensin converting enzyme inhibitors on the progression of non-diabetic renal disease: a meta-analysis of randomized trials. Ann Int Med 1997; 127: 337-45
22. Lavie CJ, Ventura HO, Messeril FH. Regression of increased left ventricular mass by antihypertensives. Drugs 1991; 42: 945-61
23. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 725-7
24. Pfeffer M, Braunwald E, Moye L, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival And Ventricular Enlargement trial. N Engl J Med 1992; 327: 669-77
25. The seventh report on the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72
26. Gazdick LP, Maxwell M, Ruff D, et al. A double-blind, randomized, parallel, active-controlled study to evaluate the antihypertensive efficacy and safety of losartan in patients with severe hypertension [abstract]. Am J Hypertens 1994; 7 (Pt 2): 100A
27. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptor antagonists. N Engl J Med 1996; 334: 1645-9
28. Azizi M, Guyene TT, Chatellier G, et al. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997; 29: 634-40
29. Miller K, Aitken B, Rodel Jr PV, et al. Enalapril, a well tolerated and efficacious agent for the pediatric hypertensive patient. J Cardiovasc Pharmacol 1987; 10: S154-6
30. Mirkin BL, Newman TJ. Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the International Collaborative Study Group. Pediatrics 1985; 75: 1091-100
31. O'Dea RF, Mirkin BL, Alward CT, et al. Treatment to neonatal hypertension with captopril. J Pediatr 1988; 113: 403-6
32. Tack ED, Perlman JM. Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr 1988; 112: 805-10
33. Wells TG, Bunchman TE, Kearns GL. Treatment of neonatal hypertension with enalaprilat. J Pediatr 1990; 117: 664-7
34. Jafar TH, Pereira JG. A cautionary note for nephrologists: is it time to abandon the use of dihydropyridine calcium channel blockers? (editorial). Semin Dialysis 1999; 12 (3): 137-9
35. Tobe S, Epstein M. The use of calcium antagonists in the treatment of hypertensive persons with kidney disease. Curr Hypertens Reports 2000; 4: 191-4
36. Griffin KA, Bidani AK. Calcium-channel blockers and the progression of renal disease. Curr Hypertens Reports 1999; 1: 436-45
37. Griffin KA, Picken MM, Bakris GI, et al. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int 1999; 55: 1849-60
38. Ruggenti P, Perna A, Benini R, et al. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. J Am Soc Nephrol 1998; 9: 2096-101
39. Hayashi K, Ozawa Y, Fujiwara K, et al. Role of actions of calcium antagonist on efferent arterioles: with special references to glomerular hypertension. Am J Nephrol 2003; 23 (4): 229-44
40. Triggs DL. Mechanisms of action of calcium channel antagonists: calcium antagonists in clinical medicine. Philadelphia (PA): Hanley and Belfus, 1-26
41. Toyo-Oka T, Nayler WG. Third generation calcium entry blockers. Blood Press 1996; 5: 206-8
42. Luscher TF, Cosentino F. The classification of calcium antagonists and their selection in the treatment of hypertension: a reappraisal. Drugs 1998; 55: 509-17
43. Drug facts and comparisons: updated monthly. St Louis (MO): Wolters Kluwer, Sep 2002: 438-45
44. Baeulis V. Antiproteinuric effect of verapamil in children with glomerulonephritis [abstract]. Pediatr Nephrol 2000; 14: C64
45. Bauer JH, Reams G. Short and long term effects of calcium entry blockers on the kidney. Am J Cardiol 1987; 59: 66A-71A
46. Kloke HL, Branten AJ, Huysmans FT, et al. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers. Kidney Int 1998; 53: 1559-73
47. Weidman P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in diabetic nephropathy. Nephrol Dial Transplant 1955; Suppl. 9: 39-45
48. Harper SJ, Moorhouse J, Abrams K, et al. The beneficial effects of oral nifedipine on cyclosporine treated renal transplant recipients. Transplant Int 1996; 9: 115-25
49. Radicio JL. Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long term trial in renal transplantation patients. J Cardiovasc Pharmacol 2000; 35: S7-11
50. Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol 2000; 15: 302-16
51. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84-112
52. Dougall HT, McLay JA. Comparative review of the adverse effects of calcium antagonists. Drug Safety 1996; 15: 91-106
53. Meraw SJ, Sheridan PJ. Medically induced gingival hyperplasia. Mayo Clin Proceed 1998; 73: 1196-9
54. Westbrook P, Bednarczyk EM, Carlson M, et al. Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine. J Periodontol 1997; 68: 645-50
55. Silverstein DM, Palmer J, Baluarte HJ, et al. Use of calcium channel blockers in pediatric renal transplant recipients. Pediatr Trans 1999; 3: 88-92
56. Flynn JT, Warnick SJ. Isradipine treatment of hypertension in children: a single-center experience. Pediatr Nephrol 2002; 17: 748-53
57. Tallian KB, Nahata MC, Turman MA, et al. Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol 1999; 13: 304-10
58. Von Vigier RO, Franscini LMD, Bianda NDF, et al. Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. J Human Hypertens 2001; 15: 387-91
59. Wyeth Pharmaceuticals Inc. Diltiazem [product information]. Morgantown (WV): Wyeth Pharmaceuticals Inc, Jan 2005
60. Buckley MMT, Grant SM, Goa KL, et al. Diltiazem: a reappraisal of its pharmacological properties and therapeutic use. Drugs 1990; 39: 757-806
61. Porter CJ, Carson A, Gillette PC. Verapamil: an effective calcium channel blocking agent for pediatric patients. Pediatrics 1983; 71: 748-55
62. PUREPAC Pharmaceutical Company. Nifedipine capsules [product information]. Elizabeth (NJ): PUREPAC Pharmaceutical Company, Jul 2004
63. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-5
64. Grossman E, Messerli FH, Grodzicki T, et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? Arch Intern Med 1990; 150: 686-7
65. Leavitt AD, Zweifler AL. Nifedipine, hypotension, and myocardial injury. Ann Intern Med 1988; 108: 305-6
66. Nobile-Orazio E, Sterzai R. Cerebral ischaemia after nifedipine treatment (case report). Br Med J (Clin Res Ed) 1981; 283 (6297): 948
67. Cherney D, Straus S. Management of patients with hypertensive urgencies and emergencies. J Gen Intern Med 2002; 17: 937-45
68. Dilmen U, Caglar MK, Senses DA, et al. Nifedipine in hypertensive emergencies of children. Am J Dis Child 1983; 137: 1162-5
69. Roth B, Herkenrath P, Krebber J, et al. Nifedipine in hypertensive crises of infants and children. Clin Exp Hypertens 1986; 89: 871-7
70. Evans JH, Shaw NJ, Brocklebank JT. Sublingual nifedipine in acute severe hypertension. Arch Dis Child 1988; 63: 975-7
71. Lopez-Herce J, Albajara L, Garcia S, et al. Treatment of hypertensive crises in children with nifedipine. Int Care Med 1988; 14: 519-21
72. Siegler RL, Brewer E. Effect of sublingual or oral nifedipine in the treatment of hypertension. J Pediatr 1988; 112: 811-3
73. Gauthier B, Trachtman H. Short-acting nifedipine [letter]. Pediatr Nephrol 1997; 11: 786-7
74. Truttman AC, Zehnder-Schlapbach S, Bianchetti MG. A moratorium should be placed on the use of short acting nifedipine for hypertensive crises [letter]. Pediatr Nephrol 1998; 12: 259-61
75. Wells TG, Graham CJ, Moss MM, et al. Nifedipine poisoning in a child. Pediatrics 1990; 86: 91-4
76. Sasaki R, Hirota K, Masuda A. Nifedipine induced transient cerebral ischemia in a child with Cockayne syndrome [letter]. Anaesthesia 1997; 52: 1236
77. Spizzirri F, Rahman R. Adverse reactions to short acting nifedipine in hypertensive crises [letter]. Pediatr Nephrol 1999; 13: 366
78. Leonard MB, Kasner SE, Feldman HI, et al. Adverse neurological events associated with rebound hypertension after using short-acting nifedipine in childhood hypertension. Pediatr Emerg Care 2001; 17: 435-7
79. Blaszak RT, Savage JA, Ellis EN. The use of short-acting nifedipine in pediatric patients with hypertension. J Pediatr 2001; 139: 34-7
80. Egger DW, Deming DD, Hamada N, et al. Evaluation of the safety of short-acting nifedipine in children with hypertension. Pediatr Nephrol 2002; 17: 35-40
81. Sinaiko AR, Daniels SR. The use of short acting nifedipine in children with hypertension: another example of need for comprehensive drug testing in children. J Pediatr 2001; 39: 7-9
82. Calvetta A, Martino S, Von Vigier RO, et al. What goes up must immediately come down! Which indication for short acting nifedipine in children with arterial hypertension? Pediatr Nephrol 2003; 18: 1-2
83. Blowey DL, Moncica I, Scolnik D, et al. The pharmacokinetics of extended release felodipine in children. Eur J Clin Pharmacol 1996; 50: 147-8
84. Moncica I, Oh PI, ul Qamar I, et al. A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension. Arch Dis Child 1995; 73: 154-6
85. McEvoy GK, editor. AHFS drug information 1996. Bethesda (MD): American Society of Health System Pharmacists, 1996: 1295-7
86. Fitton A, Benfield P. Isradipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in cardiovascular disease. Drugs 1990; 40: 31-74
87. Sandoz Pharmaceuticals. DynaCirc, isradipine [product information]. Hanover (NJ): Sandoz Pharmaceuticals, 1998
88. Hanson L. Isradapine: a profile in essential hypertension. Acta Anaesthesiol Scand 1993; 37 Suppl.: 26-8
89. Brogden RN, Sorkin EM. Isradipine: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension. Drugs 1995; 49: 618-49
90. MacDonald JL, Johnson CE, Jacobson P. Stability of isradipine in an extemporaneously compounded oral liquid. Am J Hosp Pharm 1994; 51: 2409-11
91. Johnson CE, Jacobson PA, Song MH. Isradipine therapy in hypertensive pediatric patients. Ann Pharmacother 1977; 31: 704-7
92. Strauser LM, Groshong T, Tobias JD. Initial experience with isradipine for the treatment of hypertension in children. South Med J 2000; 93: 287-93
93. Murdoch D, Heel RC. Amlodipine: a review of its pharmcaodynamic and pharmacokinetic properties and therapeutic use in cardiovascular disease. Drugs 1991; 41: 478-501
94. Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50: 560-86
95. Clavijo GA, de Clavijo IV, Weart CW. Amlodipine: a new calcium antagonist. Am J Hosp Pharm 1994; 51: 59-68
96. Lahar MS, Kelly JG, Doyle GD, et al. Pharmacokinetics of amlodipine in renal impairment. J Cardiovasc Pharmacol 1988; 12 Suppl. 7: 60-3
97. Pfammatter JP, Clericetti-Affolter C, Truttmann AC, et al. Amlodipine once-daily in systemic hypertension. Eur J Pediatr 1998; 157: 618-21
98. Khattak S, Rogan JQW, Saunders EF, et al. Efficacy of amlodipine in pediatric bone marrow transplant patients. Clin Pediatr 1998; 37: 31-6
99. Flynn JT, Smoyer WE, Bunchman TE. Treatment of hypertensive children with amlodipine. Am J Hypertens 2000; 13: 1061-6
100. Rogan JW, Lyszkiewicz DA, Blowey D, et al. A randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatr Nephrol 2000; 14: 1083-7
101. Nahata MC, Morosco RS, Hipple TF. Stability of amlodipine besylate in two liquid dosage forms. J Am Pharm Assoc 1999; 39: 375-7
102. Frishman WH. New therapeutic modalities in hypertension: focus on a new calcium channel antagonist: nicardipine. J Clin Pharmacol 1989; 29: 481-7
103. IV Nicardipine Study Group. Efficacy and safety of intravenous nicardipine in the control of postoperative hypertension. Chest 1991; 99: 393-8
104. Lambert CR, Hill JA, Nichols WM, et al. Coronary and systemic hemodynamic effects of nicardipine. Am J Cardiol 1985; 55: 652-6
105. Halpern NA, Goldberg M, Neely C, et al. Postoperative hypertension: a multicenter, prospective, randomized comparison between intravenous nicardipine and sodium nitroprusside. Crit Care Med 1992; 20: 1637-43
106. Treluyer JM, Hubert P, Jouvet P, et al. Intravenous nicardipine in hypertensive children. Eur J Pediatr 1993; 152: 712-4
107. Gouyon JB, Geneste B, Semama DS, et al. Intravenous nicardipine in hypertensive preterm infants. Arch Dis Child Fetal Neonatal Ed 1997; 76: F126-7
108. Milou C, Debuche-Benouachkou V, Semama DS, et al. Intravenous nicardipine as a first-line antihypertensive drug in neonates. Int Care Med 2000; 26: 956-8
109. Michael J, Groshong T, Tobias JD. Nicardipine for hypertensive emergencies in children with renal disease. Pediatr Nephrol 1998; 12: 40-2
110. Tenney F, Sakarcan A. Nicardipine is a safe and effective agent in pediatric hypertensive emergencies. Am J Kidney Dis 2000; 35: 1-3
111. Flynn JT, Mottes TA, Brophy PD, et al. Intravenous nicardipine for treatment of severe hypertension in children. J Pediatr 2001; 139: 38-43
112. Tobias JD, Lowe S, Deshpande JK. Nicardipine: perioperative applications in children. Paediatr Anaesth 1995; 5: 171-6
113. Tobias JD, Hersey S, Mencio GA, et al. Nicardipine for controlled hypotension during spinal surgery. J Pediatr Ortho 1996; 16: 370-3
114. Tobias JD. Nicardipine to control mean arterial pressure after cardiothoracic surgery in infants and children. Am J Therapeutics 2001; 8: 3-6
115. Nishikawa T, Omote K, Namiki A, et al. The effects of nicardipine on cerebrospinal fluid pressure in humans. Anesth Analg 1986; 65: 507-10
116. Levene MI, Gibson NA, Fenton AC, et al. The use of a calcium channel blocker, nicardipine, for severely asphyxiated newborn infants. Dev Med Child Neurol 1990; 32: 567-74